FGFR3 and diffuse astrocytoma: Diagnostically informative biomarkers and their indicated diagnoses presented in the reclassification cohort were RET M918T (MTC), TMB-High (melanoma/NSCLC)40, NRAS Q61H (melanoma), TMPRSS2-ERG fusion (PCA), FGFR3-TACC3 fusion (UC), and ATRX R781Kfs*13 (diffuse astrocytoma).